证券代码：833575 证券简称：康乐卫士 公告编号：2024-027 北京康乐卫士生物技术股份有限公司 公司于 2023 年 7 月 17 日召开第四届董事会第二十二次会议，审议通过《关于调 整公司第四届董事会专门委员会委员的议案》，鉴于公司董事会人员调整，为保证审计 委员会的正常运作，公司董事会对审计委员会委员进行相应调整，调整后的审计委员会 成员为独立董事李晓静女士、独立董事乔友林先生、非独立董事郝春利先生，仍由李晓 静女士担任主任委员。 公司于 2023 年 12 月 7 日召开第四届董事会第二十六次会议，审议通过《关于调 整第四届董事会审计委员会委员的议案》，根据《上市公司独立董事管理办法》相关规 定，公司董事会对公司审计委员会部分委员进行调整，调整后的审计委员会成员为独立 董事李晓静女士、独立董事韩强先生、未在公司担任高级管理人员的非独立董事陶涛先 生，仍由李晓静女士担任主任委员。 公司董事会审计委员会成员符合监管要求及《公司章程》等相关文件的规定。 二、审计委员会会议召开情况 | | | | 会议时间 | 会议名称 | 审议事项 | 审议结果 | | --- | --- | --- | --- ...

中信证券股份有限公司 关于北京康乐卫士生物技术股份有限公司 2023 年度募集资金存放与实际使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京康乐卫士生 物技术股份有限公司（以下简称"康乐卫士"、"发行人"或"公司"）向不特定合格投资者 公开发行股票并在北京证券交易所上市的保荐机构，根据《证券发行上市保荐业务管理 办法》、《北京证券交易所股票上市规则（试行）》等相关规定，对公司 2023 年度募 集资金存放与使用情况进行了专项核查，具体情况如下： 一、募集资金基本情况 （一）前次募集资金数额及资金到账时间 北京康乐卫士生物技术股份有限公司（"康乐卫士"或"公司"）自新三板挂牌及 北京证券交易所（以下简称"北交所"）上市以来共计完成五次募集资金计划，其中， 2019 年新三板第一次股票发行和 2019 年新三板第二次股票发行募集资金已于 2022 年 12月31日之前全部使用完毕。2023年公司存续的募集资金计划共三次，具体情况如下： 1、2023 年北交所公开发行募集资金 2023 年 1 月 20 日，中国证券监督管理委员会下发《关于同意北京康乐卫士生物技 术股份有限公司 ...

证券代码：833575 证券简称：康乐卫士 公告编号：2024-028 北京康乐卫士生物技术股份有限公司 董事会审计委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况报告 2022 年度末合伙人数量：229 人 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性承担个别及连带法律责任。 根据《公司法》《证券法》《上市公司治理准则》《国有企业、上市公司选聘会计 师事务所管理办法》和北京康乐卫士生物技术股份有限公司（以下简称"公司"）的《公 司章程》《董事会专门委员会议事规则》等规定和要求，董事会审计委员会本着勤勉尽 责的原则，恪尽职守，认真履职。现将董事会审计委员会对安永华明会计师事务 所（特殊普通合伙）（以下简称"安永华明"）2023 年度履职评估及履行监督 职责的情况报告如下： 一、2023 年年审会计师事务所基本情况 （一） 会计师事务所基本情况 会计师事务所名称：安永华明会计师事务所（特殊普通合伙） 成立日期：1992 年9 月2 日 组织形式：特殊普通合伙 注册地址：北京市东城区东长安街1 号东方广场安永 ...

证券代码：833575 证券简称：康乐卫士 公告编号：2024-032 北京康乐卫士生物技术股份有限公司 关于召开 2023 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2023 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次会议的召集、召开、议案审议程序符合《公司法》等有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简称"中国结 算"）持有人大会网络投票系统对有关议案进行投票表决，为有利于投票意见的 顺利提交，请拟参加网络投票的投资者在上述时间内及早登录中国结算网上营业 厅（网址：inv.chinaclear.cn）或关注中国结算官方微信公众号（"中国结算营 业厅"）提交投票意见。 投资者首次登陆中国结算网站进行投票的，需要首先进行身份认证。请投资 者提前访问中国结算网上营业厅 ...

证券代码：833575 证券简称：康乐卫士 公告编号：2024-021 北京康乐卫士生物技术股份有限公司 第四届监事会第二十九次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序符合相关法律、行政法规、部门规章、 规范性文件和《公司章程》等有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司〈2023 年度监事会工作报告〉的议案》 1.议案内容： 公司监事会严格按照《公司法》《公司章程》及有关法律法规开展工作，监 事会对 2023 年度工作进行总结，编制了《2023 年度监事会工作报告》。 1.会议召开时间：2024 年 3 月 21 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯相结合的方式 4.发出监事会会议通知的时间和方式：2024 年 3 月 11 日以邮件和电话方式发出 5. ...

Financial Performance - The company reported a total revenue of 833.575 million RMB for the year 2023, reflecting a significant growth compared to the previous year[3]. - The company's operating revenue for 2023 was CNY 1,779,663.64, a decrease of 6.36% compared to CNY 1,900,619.35 in 2022[26]. - The net loss attributable to shareholders for 2023 was CNY -300,908,639.52, which is a slight increase in loss of 2.76% from CNY -292,817,005.92 in 2022[27]. - The company reported a net profit margin of 12% for 2023, indicating improved operational efficiency[5]. - The company reported a basic earnings per share of -1.10 for 2023, an improvement of 3.51% from -1.14 in 2022[27]. - The company reported a significant decrease in cash and cash equivalents, dropping by 78.94% to CNY 140.14 million at the end of 2023 from CNY 665.30 million at the end of 2022[56]. - The company's total assets at the end of 2023 amounted to CNY 1,454,292,486.04, reflecting a growth of 5.13% from CNY 1,383,301,275.21 at the end of 2022[29]. - The total liabilities increased by 21.87% to CNY 547,373,386.43 in 2023, up from CNY 449,148,075.59 in 2022[29]. - The gross profit margin for 2023 was 95.58%, down from 97.42% in 2022[27]. - The cash flow from operating activities was CNY -180,208,691.46, showing a 41.90% improvement from CNY -310,179,361.91 in 2022[30]. Research and Development - Research and development efforts are focused on new vaccine technologies, with an investment increase of 25% in R&D compared to 2022[5]. - The company plans to continue its focus on the research and development of recombinant protein-based biological products, including HPV vaccines[20]. - The company has a total of 8 vaccine candidates in development, with three-valent and nine-valent HPV vaccines in Phase III clinical trials, and the fifteen-valent HPV vaccine has received clinical trial approval[38]. - The company reported R&D expenditure of ¥438,615,958.68, which represents 24,646.00% of operating income, a significant increase from 12,452.78% in the previous period[84]. - The company capitalized ¥202,551,796.10 of its R&D expenses, accounting for 46.18% of total R&D expenditure, and 67.31% of the current net profit[84]. - The company has established multiple key technology platforms for vaccine development, including structural antigen design and vaccine efficacy evaluation[98]. - The company is developing a recombinant respiratory syncytial virus vaccine, currently in preclinical research, with plans to initiate vaccine formulation studies[90]. - The company is developing an mRNA-based therapeutic HPV vaccine and expects synergies with its recombinant vaccine development platform[99]. - The company has established a high-quality R&D team and plans to continuously recruit more high-level personnel to enhance its clinical trial capabilities[102]. Market Strategy and Outlook - The company provided a positive outlook for 2024, projecting a revenue growth of 15% based on new product launches and market expansion strategies[5]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[5]. - The management discussed the importance of maintaining compliance with regulatory standards, particularly in relation to FDA approvals for new products[5]. - The company aims to launch two new vaccine products in Q2 2024, which are anticipated to contribute an additional 5% to overall revenue[5]. - The company is focused on ensuring that at least one candidate meets clinical trial application conditions each year[99]. - The company plans to expand its marketing system and sales channels in advance of product launch to mitigate market competition risks[103]. - The company is actively seeking business development collaborations to enhance the global public health and commercial value of its vaccine pipeline[43]. Corporate Governance and Management - The company has undergone significant management changes, including Liu Yongjiang's appointment as chairman and chief scientific officer, and Tao Ran's new role as CEO[174]. - The board of directors consists of 9 members, while the supervisory board has 3 members, and there are 10 senior management personnel[170]. - The company has made adjustments to its governance structure, including the appointment of new executives and the departure of others[174]. - The company has a stable governance structure and management team, with no significant changes in its industry position or operating environment[96]. - The company has implemented a share buyback program, indicating a commitment to returning value to shareholders[112]. Risks and Challenges - The company has identified intensified market competition as a significant risk, with multiple HPV vaccines currently in clinical research stages in China[103]. - The company faced a labor arbitration case, resulting in a payment of 201,386.71 yuan, which is 0.02% of the total net assets[110]. - The company has implemented measures to manage the risk of core technical personnel loss, including competitive compensation and employee retention strategies[103]. - The board of directors confirmed that there are no significant risks of delisting or major changes in risk factors for the upcoming year[10]. Assets and Liabilities - The company's total equity increased by 110.28%, from CNY 133.60 million in 2022 to CNY 280.94 million in 2023[56]. - Deferred income increased significantly by 1,752.23%, from CNY 567.37 thousand in 2022 to CNY 10.51 million in 2023[56]. - The company has a total of 8,999,525 shares held by directors and senior management, representing 3.20% of total shares[172]. - The company has no instances of shareholders or related parties occupying or transferring company funds, assets, or other resources during the reporting period[116]. Production and Compliance - The company’s production base complies with GMP standards of China, the EU, and the WHO, ensuring readiness for commercial production upon BLA approval[46]. - The company has obtained necessary qualifications and licenses for its production and operational activities[194]. - The company has established a production base in Kunming with an annual capacity of 10 million three-valent HPV vaccines and 30 million nine-valent HPV vaccines, with trial production starting on August 1, 2023[46]. Shareholder Information - The company’s major shareholders include those holding over 5% of shares, with specific details on shareholding changes provided in the report[142]. - The company’s total number of ordinary shareholders increased to 8,779 following the public offering[140]. - The company’s equity structure shows that 48.60% of shares are unrestricted, while 51.40% are subject to restrictions[140].

证券代码：833575 证券简称：康乐卫士 公告编号：2024-017 北京康乐卫士生物技术股份有限公司 | | | | | | | | 件流通股 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 5 | 陈晓 | 否 | 不适用 | D | 80,000 | 0 | 无限售条 | 0.0285% | 120,000 | | | | | | | | | 件流通股 | | | | 6 | 姜绪林 | 否 | 不适用 | D | 80,000 | 0 | 无限售条 | 0.0285% | 120,000 | | | | | | | | | 件流通股 | | | | 7 | 高文双 | 否 | 不适用 | D | 80,000 | 0 | 无限售条 | 0.0285% | 120,000 | | | | | | | | | 件流通股 | | | | 8 | 高俊 | 否 | 不适用 | D | 80,000 | 0 | 无限售条 | 0.0285% | 120,000 | | | | | | | | | 件流通股 | | | ...

北京康乐卫士生物技术股份有限公司（以下简称"公司"）已于 2024 年 1 月 29 日向香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境 外上市外资股（H 股）股票并在香港联交所主板挂牌上市（以下简称"本次发行 上市"）的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 具体内容详见公司于 2024 年 1 月 30 日在北京证券交易所信息披露平台 （www.bse.cn）披露的《关于向香港联交所递交 H 股上市申请并刊发申请资料的 公告》。 公司根据相关规定已向中国证券监督管理委员会（以下简称"中国证监会"） 报送了本次发行上市的备案申请材料并于近日获中国证监会接收。 公司本次发行上市尚需取得中国证监会、香港证券及期货事务监察委员会和 香港联交所等相关政府机关、监管机构、证券交易所的批准、核准或备案，该事 项仍存在不确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请 广大投资者关注后续公告，注意投资风险。 特此公告。 证券代码：833575 证券简称：康乐卫士 公告编号：2024-016 北京康乐卫士生物技术股份有限公司 关于发行境外上市外资股（H 股）备案申请材料获中国 ...

Financial Performance - The total revenue for 2023 was CNY 1,779,663.64, a decrease of 6.36% compared to the previous year[4] - The net loss attributable to shareholders was CNY 301,265,684.43, an increase of 2.89% year-on-year[5] - The net loss attributable to shareholders after deducting non-operating gains and losses was CNY 314,030,201.46, up 6.79% from the previous year[5] - Basic loss per share improved to CNY 1.11, a decrease of 51.53% compared to the previous year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 1,457,159,620.40, an increase of 5.34% from the beginning of the period[5] - Shareholders' equity attributable to the company was CNY 906,562,054.70, a decrease of 2.95% from the beginning of the period[5] - The share capital increased to CNY 280,940,000.00, reflecting a growth of 110.28%[6] - The net asset value per share attributable to shareholders was CNY 3.23, down 53.79% from the beginning of the period[5] Operational Insights - The overall operational situation of the company in 2023 was reported as good, with significant progress in ongoing projects[5] Cautionary Notes - The company emphasizes that the financial data is preliminary and unaudited, urging investors to be aware of investment risks[7]

Financial Performance - The company expects a net loss attributable to shareholders of 301.27 million yuan for the year 2023, compared to a net loss of 292.82 million yuan in the previous year, indicating a decline in performance [4]. - The primary reason for the expected loss is the ongoing research and development of vaccine products, with no vaccine products having been launched for sale as of December 31, 2023 [5]. Financial Data Integrity - The financial data presented is preliminary and has not been audited by an accounting firm, emphasizing the need for investors to be aware of investment risks [2][6].